---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-046091"
form_type: "8-K/A"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:23:15.457560+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx Q2 revenue up 3% to $14M, GAAP net loss of $3.9M, cuts FY 2022 outlook

## Summary
- GAAP net loss of $3.9M ($0.21/sh) vs prior-year net income of $0.4M ($0.02/sh).
- Non-GAAP net income of $0.7M ($0.04/sh) down from $1.8M ($0.10/sh) a year ago.
- Gross margin improved to 64% from 59%; revenue of $14.0M, +3% YoY.
- FY 2022 revenue guidance lowered to $62-68M (1-11% growth); gross margin 59-62%.
- Share repurchase program authorized up to $20M; 232,745 shares bought at avg $23.02.

## SEC filing metadata
- accession: 0001213900-22-046091
- form_type: 8-K/A
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390022046091/0001213900-22-046091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390022046091/ea164114-8ka1_optimize.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-046091
- JSON: https://secwatch.observer/filing/0001213900-22-046091.json
- Plain text: https://secwatch.observer/filing/0001213900-22-046091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.